Ocular Therapeutix Inc (NASDAQ:OCUL) has a beta value of 1.46 and has seen 3.01 million shares traded in the last trading session. The company, currently valued at $1.35B, closed the last trade at $8.51 per share which meant it gained $0.86 on the day or 11.24% during that session. The OCUL stock price is -38.31% off its 52-week high price of $11.77 and 52.29% above the 52-week low of $4.06.
The consensus among analysts is that Ocular Therapeutix Inc (OCUL) is Buy stock at the moment, with a recommendation rating of 1.09. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.28.
Ocular Therapeutix Inc (NASDAQ:OCUL) trade information
Sporting 11.24% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the OCUL stock price touched $8.51 or saw a rise of 1.5%. Year-to-date, Ocular Therapeutix Inc shares have moved -0.35%, while the 5-day performance has seen it change 30.92%. Over the past 30 days, the shares of Ocular Therapeutix Inc (NASDAQ:OCUL) have changed 12.42%.
Wall Street analysts have a consensus price target for the stock at $19, which means that the shares’ value could jump 55.21% from current levels. The projected low price target is $19.0 while the price target rests at a high of $19.0. In that case, then, we find that the current price level is -123.27% off the targeted high while a plunge would see the stock gain -123.27% from current levels.
Ocular Therapeutix Inc (OCUL) estimates and forecasts
The company’s shares have gained 1.43% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 12.48%.
8 analysts offering their estimates for the company have set an average revenue estimate of 17.18M for the current quarter. 8 have an estimated revenue figure of 17.89M for the next ending quarter. Year-ago sales stood 14.77M and 16.44M respectively for this quarter and the next, and analysts expect sales will grow by 16.31% for the current quarter and 12.48% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 8.51% over the past 5 years. Earnings growth for 2025 is a modest 0.57% while over the next 5 years, the company’s earnings are expected to increase by 5.98%.
OCUL Dividends
Ocular Therapeutix Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Ocular Therapeutix Inc (NASDAQ:OCUL)’s Major holders
The top two institutional holders are SUMMER ROAD LLC with over 14.89 million shares worth more than $101.82 million. As of 2024-06-30, SUMMER ROAD LLC held 8.9767% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 11.52 million shares as of 2024-06-30. The firm’s total holdings are worth over $78.8 million and represent 8.7261% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . As of Dec 31, 2024 , the former fund manager holds about 2.92% shares in the company for having 4.64 shares of worth $39.51 million while later fund manager owns 4.21 shares of worth $35.86 million as of Dec 31, 2024 , which makes it owner of about 2.65% of company’s outstanding stock.
